Oncology for the Inquisitive Mind

education podcast on cancer treatment trials and cure Josh Hurwitz Michael Fernando doctor

“In learning, you will teach,
and in teaching, you will learn.”

Phil Collins

Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, practice-changing updates, and regular interviews with renowned oncology specialists. 

Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.

Newsreel

Newsreel
DESTINY-Breast 03 - The rise of the ADC
DESTINY-Breast 03 - The rise of the ADC
Read More →
Enrolment in Clinical Trials: Do Patients Benefit?
Enrolment in Clinical Trials: Do Patients Benefit?
Read More →
Hypercalcaemia of Malignancy: A Foreboding Entity
Hypercalcaemia of Malignancy: A Foreboding Entity
Read More →
Renal Toxicity with Chemotherapy and ICI - an Under-Appreciated Toxicity
Renal Toxicity with Chemotherapy and ICI - an Under-Appreciated Toxicity
Read More →
Aggressive-Variant Prostate Cancer (AVPC) - a success story’s Dark Side
Aggressive-Variant Prostate Cancer (AVPC) - a success story’s Dark Side
Read More →
Management of Older Patients with Head and Neck Cancer - a Forest of Confusing Evidence
Management of Older Patients with Head and Neck Cancer - a Forest of Confusing Evidence
Read More →
A Better Prostate Screening Regimen? Early Results from ProScreen
A Better Prostate Screening Regimen? Early Results from ProScreen
Read More →
SENOMAC Trial - Is the Answer Less Slice and Dice?
SENOMAC Trial - Is the Answer Less Slice and Dice?
Read More →
Immunotherapy in Kidney Transplant Patients - the Final Frontier for ICI?
Immunotherapy in Kidney Transplant Patients - the Final Frontier for ICI?
Read More →
PALOMA-2 Final Update: Is This the End of Palbociclib?
PALOMA-2 Final Update: Is This the End of Palbociclib?
Read More →
Duration of Immunotherapy - Is Two Years Enough?
Duration of Immunotherapy - Is Two Years Enough?
Read More →
Mechanisms of Primary and Secondary Resistance to Immunotherapy
Mechanisms of Primary and Secondary Resistance to Immunotherapy
Read More →
NeoSTAR - ADCs in Neoadjuvant Triple Negative Breast Cancer?
NeoSTAR - ADCs in Neoadjuvant Triple Negative Breast Cancer?
Read More →
Can diclofenac prevent Hand-Foot Syndrome (HFS)?
Can diclofenac prevent Hand-Foot Syndrome (HFS)?
Read More →
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer: Battle of the IOs
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer: Battle of the IOs
Read More →
Hyperprogression and Pseudoprogression - Faster than the Speed of Light
Hyperprogression and Pseudoprogression - Faster than the Speed of Light
Read More →
Spotlight: FGFR Inhibitors in Biliary Tract Cancer - The Truth is Out There!
Spotlight: FGFR Inhibitors in Biliary Tract Cancer - The Truth is Out There!
Read More →
ADAURA - adjuvant osimertinib reigns supreme
ADAURA - adjuvant osimertinib reigns supreme
Read More →
Tick Tock - A Metronomic Approach to Treatment of Nasopharyngeal Cancer, not the Social Media
Tick Tock - A Metronomic Approach to Treatment of Nasopharyngeal Cancer, not the Social Media
Read More →
OPAL - For when osimertinib is not enough…
OPAL - For when osimertinib is not enough…

Osimertinib has been nothing short of a game-changer for a segment of lung cancer sufferers. For the approximately 30% of patients with non-squamous non-small cell lung cancer (NSCLC) who carry an EGFR mutation, osimertinib has stretched out the average expected survival from months to years. To date, osimertinib has only been studied as a single agent. Until now…..

Read More →
CLEAR Trial Update - ESMO 2022
CLEAR Trial Update - ESMO 2022

At the ESMO Annual Congress in 2022, study author Dr Camillo Porta provided an update on the study results in all IMDC risk groups, with a median follow-up of 33.7 months…

Read More →
ONKOTEV Risk Prediction Score for VTE in Cancer Patients
ONKOTEV Risk Prediction Score for VTE in Cancer Patients

In an article published in JAMA Oncology in February 2023, Cella et al. have published validation of a new risk prediction model with the ONKOTEV-2 study for outpatients with cancer.

Read More →

Partners